Due to COVID-19, new study enrollment is being assessed on a case by case basis. If you have any questions please call our central phone number at 616-391-1230.

Lymphoma Clinical Trials

Narrow List by Age:

(Refer to Clinical Summary for age requirements)

Lymphoma

Protocol Alliance A051301
Cancer Type: Lymphoma
Fast Facts

A Randomized Double-Blind Phase III Study of Ibrutinib During and Following Autologous Stem Cell Transplantation Versus Placebo in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma of the Activated B-Cell Subtype

Protocol Alliance A051701
Cancer Type: Double-hit and double-expressing lymphomas
Fast Facts

Randomized Phase II/III Study of Venetoclax (ABT199) Plus Chemoimmunotherapy for MYC/BCL2 Double-Hit and Double Expressing Lymphomas

Please check out the rare protocol list to locate other studies within this disease site.

Protocol SWOG S1608
Cancer Type: FOLLICULAR LYMPHOMA
Fast Facts

Randomized Phase II Trial in Early Relapsing or Refractory Follicular Lymphoma

Please check out the rare protocol list to locate other studies within this disease site.

Protocol EA4181
Cancer Type: Untreated Mantle Cell lymphoma
Fast Facts

A Randomized 3-Arm Phase II Study Comparing 1.) Bendamustine, Rituximab and High Dose Cytarabine (BR/CR) 2.) Bendamustine, Rituximab, High Dose Cytarabine and Acalabrutinib (BR/CR-A), and 3.) Bendamustine, Rituximab and Acalabrutinib (BR-A) in Patients <70 years old with Untreated Mantle Cell Lymphoma 

Please check out the rare protocol list to locate other studies within this disease site.

Protocol SWOG S1826
Cancer Type: ADVANCED STAGE CLASSICAL HODGKIN LYMPHOMA
Fast Facts

A Phase III, Randomized Study of Nivolumab (Opdivo) Plus AVD or Brentuximab Vedotin (Adcetris) Plus AVD in Patients (Age >/= 12 Years) with Newly Diagnosed Advanced Stage Classical Hodgkin Lymphoma

Protocol E4412
Cancer Type: Refractory Hodgkin Lymphoma

Randomized Phase II Study of the Combinations of Ipilimumab, Nivolumab and Brentuximab Vedotin in Patients with Relapsed/Refractory Hodgkin Lymphoma

Please check out the rare protocol list to locate other studies within this disease site.

Protocol COG ANHL12P1
Cancer Type: ALCL
Fast Facts

A Randomized Phase II Trial of Brentuximab Vedotin (SGN35, NSC# 749710), or Crizotinib (NSC#749005, Commercially Labeled) in Combination With Chemotherapy for Newly Diagnosed Patients With Anaplastic Large Cell Lymphoma (ALCL) 

Patient must be < 22 Years of Age.

Please check out the rare protocol list to locate other studies within this disease site.

Cancer clinical trials are research studies for developing better ways of detecting, treating, and eventually preventing cancer. By taking part in a clinical trial, you are among the first to receive new research treatments before they are widely available. Your participation in a clinical trial will influence the future direction of cancer care.

If you are interested in participating in a clinical trial, consult with your physician. Please note: clinical trials are not risk free. Patients must explore the options that are best for their individuals needs with the help of their physician.